Using next-generation sequencing, the UPSeq test assesses 15 biomarkers to find aggressive prostate cancer that can be missed by biopsies or imaging tests.
San Francisco, CA (UroToday.com) — Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based, multi-biomarker test to detect aggressive prostate cancer that performed better than existing biomarker tests in initial preclinical evaluations.